Pfizer Inc.

Pfizer Inc. Earnings Recaps

PFE Health Care 4 recaps
Next earnings: February 2, 2027 (estimated) · full calendar
Q3 2026 Nov 6, 2026

Pfizer shares fell 2.2% after earnings, a roughly flat reaction. The company raised full-year 2026 revenue and adjusted EPS guidance, while the call highlighted growth in acquired products and ongoing investment in its pipeline.

Key takeaways
  • Launched and acquired products grew 32% operationally in the quarter; acquired products grew 37%.
  • Seagen’s legacy portfolio grew 39% year over year in the U.S., driven by Padcev.
  • Biohaven grew 33% operationally, with management citing demand and commercial execution amid competition in oral CGRP.
  • Pfizer plans 10 active or planned Phase 3 obesity trials in 2026 and is working toward a first potential berobenatide approval in 2028.
  • Management cited financial discipline and productivity improvements as margin contributors, but the provided remarks do not include specific quarterly financial results or the details of the raised guidance.
Q2 2026 Aug 6, 2026

Pfizer’s shares rose 3.1% following Q2 2026 results, driven primarily by raised revenue guidance and strong growth in acquired product portfolios, signaling investor approval of the company’s strategic execution and pipeline progress.

Key takeaways
  • Raised full-year 2026 revenue guidance midpoint, while reaffirming adjusted diluted EPS guidance.
  • Acquired product revenues grew 25% operationally year-over-year, excluding prior year’s one-time items.
  • Legacy Seagen U.S. portfolio advanced with 21% year-over-year revenue growth, adjusting for onetime stocking.
  • Pipeline progress includes 3 regulatory approvals, 6 key data readouts, and 8 pivotal study starts in first half of 2026.
  • Cost savings initiatives updated with an additional $1 billion from realignment and $3 billion total expected from manufacturing optimization through 2029.
Q1 2026 May 7, 2026

Pfizer's shares were little changed, rising 0.9% after earnings as the company's quarterly results and outlook broadly met market expectations without providing a clear catalyst for a larger move.

Key takeaways
  • Total revenues and adjusted diluted EPS exceeded internal expectations, supporting steady near-term financial performance.
  • Launched and acquired products grew 22% operationally, with oncology (notably Seagen) achieving 20% year-over-year revenue growth.
  • Nurtec contributed 41% operational growth, driven by strong demand across acute and preventive migraine treatments.
  • Progress on R&D remains on track, with three positive Phase III readouts and plans for approximately 20 pivotal study starts in 2026.
  • Legal developments, including Vyndamax patent settlements and a favorable Belgian court ruling on Comirnaty contracts, enhance long-term growth visibility and cash flow prospects.
Q3 2025 Nov 5, 2025

Pfizer reported strong third-quarter 2025 results, leveraging strategic partnerships and clinical advancements to enhance its competitive position in the pharmaceutical landscape.

Key takeaways
  • Established a landmark agreement with the U.S. government, addressing key policy impacts and committing to U.S. manufacturing investments.
  • Advanced the proposed acquisition of Metsera, with potential to enhance Pfizer’s portfolio in obesity treatments despite external competitive offers.
  • Received encouraging Phase II clinical data for SSGJ-707, with plans for a robust clinical development program to unlock its potential.
  • Presented breakthrough results at ESMO from multiple oncology studies, reinforcing portfolio strength and expanding addressable patient populations across various cancer types.